Web Exclusives

Among the complex causes for the disparities in cancer outcomes, lacking or insufficient health insurance plays a major role. Good insurance coverage contributes to earlier diagnosis and improved treatment for patients with different types of cancers. Read More ›

Doctors and nurses are heroes for the care they provide, and researchers are heroes for the breakthrough treatments and medications they develop. Let us not overlook the incredible contributions of oncology social workers in the journey of a patient with cancer. Read More ›

Based on current and evolving scientific evidence, the cancer prevention guidelines have been shifting from a nutrient-centric approach to a more holistic approach of diet that is characterized as dietary patterns. Read More ›

Cancer affects all races, ethnicities, sexual orientations, genders, and nationalities. Read More ›

Cervical cancer during pregnancy can be successfully managed with a multidisciplinary treatment team and an individualized treatment strategy that optimizes maternal treatment while considering fetal safety. Read More ›

On November 22, 2021, the FDA approved Fyarro (sirolimus protein-bound particles for injectable suspension (albumin-bound); from Aadi Bioscience) for adults with locally advanced, unresectable or metastatic malignant perivascular epithelioid-cell tumor (PEComa), a rare type of mesenchymal tumors that can occur in any part of the body.

Read More ›

On August 17, 2021, the FDA accelerated the approval of Jemperli (dostarlimab-gxly; from GlaxoSmithKline) injection, an immunotherapy and a PD-1 inhibitor, for the treatment of all adults with recurrent (coming back) or advanced mismatch repair-deficient (dMMR) solid tumors, including lung cancer, that progressed during or after systemic therapy and for whom there are no satisfactory alternative treatment options. Read More ›

Although we are entering another winter with the ongoing prevalence of the coronavirus, we have come a long way since the initial outbreak. Here are some reasons for patients to be optimistic for the season. Read More ›

The combination of acalabrutinib, venetoclax, and obinutuzumab has been shown to be an active regimen in previously untreated patients with CLL. Read More ›

During the first 13 months of the pandemic, COVID-19 continued to result in high hospitalization rates among patients with CLL. Read More ›